Chapter 3. Discovery of Pazopanib: A Pan Vascular Endothelial Growth Factor Kinase Inhibitor

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Philip A. Harris1 and
  2. Jeffrey A. Stafford2

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch3

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Harris, P. A. and Stafford, J. A. (2009) Discovery of Pazopanib: A Pan Vascular Endothelial Growth Factor Kinase Inhibitor, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch3

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. 1

    GlaxoSmithKline R&D, Collegeville, PA 19426, USA

  2. 2

    Takeda San Diego, Inc., San Diego, CA 92121, USA

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961

SEARCH

Keywords:

  • pazopanib discovery - pan vascular endothelial growth factor kinase inhibitor;
  • screening hits and structure-based design;
  • nonclinical toxicology

Summary

This chapter contains sections titled:

  • Introduction

  • Early VEGFR2 Kinase Inhibitor Lead Structures

  • Screening Hits and Structure-Based Design

  • Medicinal Chemistry Strategy and Synthetic Route

  • Structure-Activity Relationship of Indazolylaminopyrimidines

  • Properties of Pazopanib (GW 786034)

  • Nonclinical Toxicology

  • Clinical Studies

  • Acknowledgments

  • References